Nanobiotix: Declaration of total voting rights and shares making up the Company’s share capital

0

PARIS–(COMMERCIAL THREAD) – Regulatory news:

Nanobiotix (Paris: NANO) (NASDAQ: NBTX):

Market: Euronext Paris / Nasdaq

Euronext compartment: B

ISIN code: FR0011341205

Nasdaq: NBTX

Bloomberg: NANO: FP

Reuters: NANO.PA

Website: www.nanobiotix.com

Dated

Number of outstanding shares

Total number of voting rights

Total voting rights, gross (1)

Total voting rights,

report (2)

November 30, 2021

34 825 872

36,003,389

35 985 166

(1) The total number of gross (or “theoretical”) voting rights is used as a basis for calculating threshold crossings. In accordance with article 223-11 of the AMF General Regulations, this number is calculated on the basis of all the shares to which the voting right is attached, including those whose voting rights have been suspended.

(2) The total number of net voting rights (or “exercisable at a General Meeting”) is calculated without taking into account the shares for which the voting rights have been suspended. It is distributed to ensure that the public is properly informed, in accordance with the AMF opinion of July 17, 2007.

***

About NANOBIOTIX: http://www.nanobiotix.com

Nanobiotix is ​​an advanced clinical biotechnology company developing disruptive physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity.

The company’s philosophy is rooted in the concept of pushing the boundaries of what is known to expand the possibilities of human life. Established in 2003, Nanobiotix is ​​headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain and Germany. Nanobiotix has been listed on Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York since December 2020.

Nanobiotix owns over 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) central nervous system disorders.

The company’s resources are mainly devoted to the development of its flagship product candidate, NBTXR3, which is the product of its proprietary oncology platform and has already obtained marketing authorization in Europe for the treatment of patients with sarcoma. soft tissue under the Hensify® brand.

For more information on Nanobiotix, visit us at http://www.nanobiotix.com or follow us on LinkedIn and Twitter.

Share.

Comments are closed.